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Nonmelanoma skin carcinoma (NMSC) is the most frequent cancer in the USA with over 1.3 million new diagnoses a year;
however due to an underappreciation of its associated mortality and growing incidence and its ability to be highly aggressive, the
molecular mechanism is not well delineated. Whereas the molecular proﬁles of melanoma have been well characterized, those for
cutaneous squamous cell carcinoma (cSCC) have trailed behind. This importance of the new staging paradigm is linked to the
ability currently to better clinically cluster similar biologic behavior in order to risk-stratify lesions and patients. In this paper we
discuss the trends in NMSC and the etiologies for the subset of NMSC with the most mortality, cutaneous SCC, as well as where
the ﬁeld stands in the discovery of a molecular proﬁle. The molecular markers are highlighted to demonstrate the recent advances
in cSCC.
1.Introduction
Nonmelanoma skin carcinoma (NMSC) is the most frequent
cancer in the USA and worldwide [1]; it has been increasing
inoverallincidencesincethe1960’satarateof3–8%peryear
[2]. With over 1.3 million new diagnoses of NMSC a year in
theUnitedStates[3],itisboththediversityoftypes,ofwhich
there are 82, and biologic variability in phenotype that make
the analysis of NMSC even more challenging. Although the
incidence of basal cell carcinoma (BCC) exceeds cSCC by a
5:1 ratio, cSCC is associated with the burden of mortality
with a disease-speciﬁc yearly mortality rate of 1% per year
as reported in the early 1990’s [4]. Despite the fact that
the majority of these tumors present at early stages, cSCC
accounts for the majority of NMSC deaths [5] and 20% of all
skin-cancer-related deaths [6].
Multiple etiologies exist for cSCC, including environ-
mental, genetic, viral and altered host immunity and virally
mediated. The high incidence of cSCC and BCC is caused by
themutageniceﬀectsofultraviolet(UV)lightwhichisinten-
siﬁed by geographic latitude [1, 7]. cSCC and BCC are more
common in fair skinned and anatomic sites exposed to the
sun,suchashead, neck, andextremities: headandneck is the
most common site. Other known risk factors are male sex,
advanced age, immunosuppression (induced or acquired),
humanpapillomaviruses(HPV),chronicinﬂammation,and
genetic diseases manifested in the skin [7–9]. Immunocom-
promised states are associated with a marked escalation of
cSCC of up to 64–250 times greater than that in the general
population compared to the 10-fold increased risk in BCC,
causing a reversal of the typical ratio in immunocompetent
individuals from 5:1 to a range between 1:1.8 and 1:15 [10,
11]. Immunosuppression signiﬁcantly impacts the biology
of cSCC. In solid organ transplant patients, cSCC tumors
tend to be numerous, exhibit a strong propensity to recur,
and metastasize at a high rate regardless of lesional size [12].
Malignant lesions develop within 10 years after organ trans-
plantation and up to 80% of these lesions contain HPV DNA2 International Journal of Surgical Oncology
[13]. HPV has also been associated with cSCC with evidence
of a higher viral load of HPV DNA in immunosuppressed
patients [13, 14]. Likewise cSCC that arises in sites of chronic
inﬂammation, such as scars, sinus tracts, and burns, can also
demonstrate more aggressive clinical behavior and a greater
propensity to metastasize with an overall metastatic rate of
40% [6, 15]. Cutaneous genetically inherited skin conditions
thathaveaknownpropensityofriskfordevelopingcSCCare
albinism, xeroderma pigmentosum, and epidermodysplasia
verruciformis [5, 16, 17].
2. Staging
With a cure rate of greater than 90% for the routine lesion,
and the large number of low risk lesions, the signiﬁcance
of the diverse spectrum and numerous subtypes of cSCC
has been underappreciated given the often quoted 5-year
recurrence and metastatic rates of 8% and 5%, respectively
[6, 18, 19]. However recent changes to the American Joint
Committee on Cancer Staging (AJCC) presented in the 7th
Edition focus on identifying clinical parameters that portend
a worse prognosis to identify and stage appropriately that
subset of cSCC that progresses to metastatic disease [9]. The
high risk characteristics determined by the 7th Edition AJCC
Staging Manual include lesional size (>2cm), and high risk
features such as a depth of invasion (>2mm, ≥Clark level
IV), perineural invasion, tumor grade (poorly diﬀerentiated
or undiﬀerentiated), as well as high-risk anatomic sites (see
Table 1). The paradigm shift in the 7th Edition recognizes
that the classiﬁcation of lesions with similar histopathologic
featuresismorelikelytohavesimilaraggressivebehaviorand
thefeatureschosenwerebasedonthatbehavior.Forinstance,
tumor grade alone is signiﬁcantly associated with mortality
givena5-yearcureaftertherapyof61.5%forpoorlydiﬀeren-
tiated cSCC compared to 94.6% for well diﬀerentiated cSCC
[6]. High risk histologic features were deﬁned as showing
poor diﬀerentiation, spindle cell characteristics, necrosis,
high mitotic activity, and deep invasion [9]. Both the depth
of invasion and presence of perineural invasion signiﬁcantly
correlate with prognosis: it clearly has been shown that
thicker lesions have a higher rate of nodal metastases and
recurrence. In fact a depth of >4mm thickness or ≥Clark
Level IV is associated with a twofold increased rate of
recurrence or 5-fold increase metastatic rate [6]. Similarly,
perineural invasion is associated with a 5-fold increase in
both the recurrence rate and metastatic rate [20]. Although
not identiﬁed in the 7th Edition, other histologic features
that are important in prognosis include lymphovascular
invasion and the presence of inﬂammatory features such as
the presence of eosinophils and plasma cells [21]. cSCC in
immunocompromised patients or those that arise in scars,
sinus tracts, or burns all demonstrate a more aggressive bio-
logic phenotype with a greater metastatic rate of up to 40%
[6, 15, 22] .S os u b s e t sw i t haw o r s ep r o g n o s i sa r ec r i t i c a lt o
correctly stage and classify together in order to appropriately
reveal a previously unrecognized metastatic potential. Like-
wise recurrent or persistent disease portends a worse survival
of78%5-yearsurvivalcomparedto97%foraprimarylesion
[20, 23]. Since the incidence of metastatic cSCC is low, the
Table 1: High risk factors for NMSC tumor characteristics∗.
Histologic diﬀerentiation
Poor diﬀerentiation
Spindle cell characteristics
Necrosis
High mitotic activity
Deep invasion
Depth of invasion
>2mm
Clark level 3IV
Perineural invasion
High risk anatomic sites
Nonglabrous Lip
Ear
Advanced T stage (T3 and T4)
Bony extension or involvement
Maxilla, mandible, orbit, temporal bone
Perineural invasion
Invasion of skull base
Invasion of axial or appendicular skeleton
∗7th Edition of American Joint Commission on Cancer Staging Manual
[18].
outcome of metastatic cSCC is not universally recognized as
dismal at a-5 year survival of less than 35% [6].
Prognostic features have not been universally accepted in
cSCCandthehistologicfeaturesdelineatedaboveareadvised
for uniformity in standardizing clinical staging guidelines.
Since cSCC is typically deemed to have a good prognosis,
the variants with the worst biology, by not being grouped
together, are underpowered numerically in an outcome
a n a l y s i s .T h u st h ev a r i e t yo fs u b t y p e so fc S C Cc e r t a i n l y
necessitates a comprehensive clinicopathologic classiﬁcation
system to group variants of SCC based on their biologic
aggressiveness or indolence. The 7th Edition introduces the
histologic features that need to be tracked and classiﬁed;
yet a clinicopathologic classiﬁcation system would allow
lesions to be stratiﬁed based on biologic behavior and thus
patients accordingly to optimize therapy. Clinicopathologic
classiﬁcation of cSCC has been characterized by Cassarino
et al. [24] to stratify lesions based on their malignant poten-
tial (Table 2). In the era of personalized medicine, molec-
ular markers have been used in many tumors to prog-
nosticate and risk-stratify patients. Given the relative lack
of recognition of the growing incidence of cSCC and the
inability to track the worst subset of cSCC given the abun-
dance of low risk lesions and the practice of not banking or
staging lesions, these molecular studies have been relatively
limited compared to the ﬁeld of melanoma. A summary of
the current literature on the molecular markers in cSCC
highlights some promising areas of research.
3. Pathogenesis
3.1. Viral Pathogenesis. The increased incidence of cSCC in
immunocompromised patients compared to BCC suggests aInternational Journal of Surgical Oncology 3
Table 2: Clinicopathologic classiﬁcation for cSCC∗.
High risk behavior cSCC
Bowen’s disease with invasion
Adenosquamous carcinoma
cSCC in proliferating pilar tumor/cysts
Tricholemmal cysts
Epidermoid cysts
Desmoplastic cSCC
De novo cSCC
cSCC in chronic conditions
Ulcers, sinus tracts, burns
Osteomyelitis
Chronic inﬂammatory disorders
Radiation-induced cSCC
Indeterminate risk cSCC
Clear cell SCC
Signet ring cell
Papillary cSCC
Pigmented cSCC
Follicular cSCC
cSCC from benign adnexal cyst
Putative cSCC versus low grade cSCC
Keratoacanthoma (KA)
Not a bona ﬁde cSCC
Low grade behavior
Giant KA,
Subungual KA
KA with Immunosuppression
∗Modiﬁed Classiﬁcation system from Cassarino et al. [24].
mechanism of viral pathogenesis. HPV is important in im-
munosuppressed patients, which are known to have higher
levels of HPV DNA in cSCC lesions. Evidence of a higher
viral load has been reported in cSCC in organ transplant
patients with up to 80% of lesions containing HPV DNA
[14].HoweverthevariablequantityofHPVinimmunocom-
petent individuals can range between 27–70% depending
on detection techniques [13, 17]. Thus the type of HPV,
β-papillomavirus species 2, is more often associated with
cSCC as opposed to the total amount of HPV DNA present
[17]. Three theories have been suggested for the mechanism
of HPV carcinogenesis: (1) UV radiation-induced immuno-
suppression to explain enhanced interaction between HPV
and UV radiation [25, 26], (2) E6/E7 oncoprotein-related
changes in p53 and Rb tumor suppressor gene, and (3)
integration of HPV DNA disrupting genomic stability
[17, 25]. Viral expression of E6 and E7 oncoproteins can
inactivate p53 and Rb tumor suppressor genes, leading to an
uncontrolled system of cell proliferation and apoptosis [27].
Association of viral pathogens such as human papillo-
mavirus (HPV) with head and neck squamous cell cancer
(HNSCC), especially oropharyngeal cancer has been recog-
nized over the past two decades. HPV16 is the most common
genotype in these tumours, whereas HPV6 and HPV11 can
also be found in a minority of these cancers, implying that
these low-risk HPV types are not entirely benign in HNSCC.
HPV DNA is closely associated with poorly diﬀerentiated
cancers, positive lymph nodes, and late-stage disease, which
portend a worse diagnosis. HPV status is also associated with
p16 expression and HPV+ tumours are less likely to harbour
p53 mutations [28] .As u b s e to fH N S C Cp a t i e n t sw h oh a d
HPV 16 infection confers a better prognosis. On the other
hand, β papillomaviruses (β-HPVs) also play a role in the
tumorigenesis of cSCC as shown by both European and US
studies [29]. However, no high-risk types have been identi-
ﬁed although there is an association of β species 1 in SCC.
Other viruses, such as polyomavirus (MCPyV) have been
shown to be causative agent in Merkel cell carcinoma [30].
3.2. Allelic Imbalance and Loss of Heterozygosity. The genetic
progression model for head and neck squamous cell car-
cinoma (HNSCC) demonstrates that loss of heterozygosity
(LOH) is common during the progression from premalig-
nant lesion to malignant tumors [31]. Tumor suppressor
genes (TSGs) are usually found in the area of loss rendering
the cells more susceptible to tumorigenesis [32].
Several regions of chromosomal loss are identiﬁed in
HNSCC. One of the most common regions, 9p21, has been
reported in both HNSCC [33] and cSCC [34]. This region
contains several TSGs, including p16INK4A (CDKN2A),
p15INK4B, and MTAP. Allelic imbalances are also found in
other regions of cSCC, including LOH on 3p, 2q, 8p, and
13 and allelic gain on 3q and 8q [35]. Such studies indicate
that allelic imbalance and LOH are recognized and relevant
eventsincSCCandcanbeusedforearlydiagnosisandtumor
surveillance.
3.3. Epigenetics. Epigenetics refers to the molecular mech-
anisms that regulate gene expression without changes in
the DNA sequence. Epigenetic alterations include DNA
methylation and histone modiﬁcations, which consist of
methylation, acetylation, phosphorylation, ubiquitination,
and sumoylation, chromatin remodeling and microRNAs
[36–38]. Changes in genomic DNA methylation associated
with cancer include global DNA hypomethylation and gene-
speciﬁc hyper- or hypomethylation. Tumor progression
involved chromatin-mediated changes such as DNA methy-
lation yet the role of histone variants in tumorogenesis is
unclear. All of these modiﬁcations of gene expression have
been associated with the development of various tumor
types, including HNSCC and cSCC [39, 40]. A higher
frequency of FOXE1 promoter hypermethylation was found
in cSCC compared to normal skin, indicating that FOXE1
may be a target for aberrant methylation in cSCC [39].
Epigenetic dysregulation is thought to be involved in
tumor biology and progression and thus may be relevant
biomarkers for clinical prognosis [39]. Promoter DNA
methylationgenepanelshavebeendescribedforscreeningof
primary HNSCC [41, 42], for determination of tumor recur-
renceandassessmentofmarginstatusduringsurgery.Recent
evidence does show that the loss of histone variants, such as
macro-H2A, positively correlates with an increasing malig-
nant phenotype of melanoma cells and that macro-H2A is4 International Journal of Surgical Oncology
a critical component of chromatin that suppresses malignant
progression of melanoma [43]. However, a determination of
methylation gene panels relevant in cSCC is yet to be estab-
lished. To date there has been no correlation of the signiﬁ-
cance of global histone modiﬁcations to prognosis in cuta-
neous SCC although studies have shown them to be applica-
b l ei ne s o p h a g e a lS C C[ 44]. A combination of diﬀerent genes
fromdiﬀerentpathwaysmayallowforabetterdetermination
oftheaggressivenessofcSCCtobetter correlatetoprognosis.
3.4. RNA and microRNA. Messenger RNA (mRNA) and
microRNA (MiRNA) proﬁles have been described in both
HNSCC and cSCC [45]. Several mRNA biomarkers for
cSCC were identiﬁed, including CCR10, CCL27, MUC4,
p16, MMP2, and MMP9 [46]. MicroRNAs play a role in
regulation of mRNA. A recent study has demonstrated that
a distinct microRNA proﬁle is modulated by UV radiation
[47].
3.5. Mitochondrial Mutation. Mitochondrial mutation in
HNSCC has been well reported; however, only a few studies
show the association of mitochondrial DNA mutation and
cSCC [48]. Several regions of mitochondrial DNA were
reported, including displacement loop (D-loop) [49]a n d
other regions [50]. Therefore, mitochondrial mutations may
correlateinthefuturewiththephenotypicbehaviorofcSCC.
4. Conclusions
The molecular mechanisms that underlie the development
of cutaneous skin cancers are poorly understood. Even the
spectrum of biologic behavior has been slow to be character-
ized given the previously very generic clinical criteria used to
distinguish low risk lesions from a more aggressive lesions.
Recent changes in the classiﬁcation of the staging paradigm
has better captured the histologic features of this more
aggressive subset to allow for a more precision in identifying
the worst subset. Incorporating a clear clinicopathologic
classiﬁcation system into stratifying lesions is necessary to
better cluster them by their biology besides just histologic
features.Thus molecular analysis can potentially proﬁle that
subset with biomarkers chosen to best correlate with the bio-
logic phenotype.
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